1. At a Glance – Blink and You’ll Miss the Cash
Cyient DLM currently trades around ₹366, nursing a ~21% fall in the last 3 months, as if Mr. Market suddenly remembered that EMS + defence = long cycles + capital hunger. Market cap sits near ₹2,900 Cr, P/E about 35.5x, ROCE a modest 11%, and ROE a sleepy 7.3%.
The latest Q3 FY26 (Quarterly Results) show ₹303 Cr revenue, down sharply 31.7% QoQ, while PAT of ₹11.2 Cr somehow stayed alive with 2.18% growth. This is classic Cyient DLM behaviour: revenue swings like a drunk fighter jet, but margins try their best to salute discipline.
Exports now form 66% of revenue, defence alone contributes 49%, and the order book of ₹2,170.5 Cr continues to be flashed like a wedding buffet—huge spread, but you still wait in line.
Working capital days? 111 days.
Yes, money goes in… and then goes on a spiritual retreat.
Curious already? Good. Let’s peel this EMS onion layer by expensive layer.
2. Introduction – EMS With a Defence Badge
Cyient DLM is not your neighbourhood “assemble iPhone covers” EMS company. This is low-volume, high-mix (LVHM) manufacturing—basically bespoke electronics for aerospace, defence, medical, and industrial customers who hate defects more than Indian auditors hate missing schedules.
The company operates under 3–5 year Master Service Agreements, meaning relationships are sticky, but revenues are lumpy. One quarter Boeing smiles, next quarter procurement freezes like North Indian winters.
Listed in July 2023, Cyient DLM came with pedigree—backed by Cyient Ltd, three decades of engineering DNA, and a solid client list including Honeywell, Thales, ABB, BEL. On paper, this screams “quality EMS”. On the cash flow statement, it screams something else.
The big promise?
India’s defence indigenisation + aerospace outsourcing + China+1.
The big reality?
Inventory
